b r i e f c o m m u n i c a t i o n s
We conducted a genome-wide association study of male breast cancer comprising 823 cases and 2,795 controls of European ancestry, with validation in independent sample sets totaling 438 cases and 474 controls. A SNP in RAD51B at 14q24.1 was significantly associated with male breast cancer risk (P = 3.02 × 10 −13 ; odds ratio (OR) = 1.57). We also refine association at 16q12.1 to a SNP within TOX3 (P = 3.87 × 10 −15 ; OR = 1.50).
Male breast cancer accounts for 1% of all breast cancer diagnoses. Family history is a significant risk factor for male breast cancer: the relative risk of breast cancer for a female with an affected brother is approximately 30% higher than for a female with an affected sister 1 . Approximately 10% of male breast cancer cases carry BRCA2 mutations, whereas BRCA1 mutation carriers are reported less frequently 2 . We performed a genome-wide association study (GWAS) for male breast cancer, predicated on the assumption that common variation contributes appreciably to the heritable risk of male breast cancer and because investigation of risk alleles for breast cancer in males may provide insight into genetic susceptibility for the disease in females.
Using Illumina OmniExpress arrays, we genotyped 920 male breast cancer cases ascertained from the UK (n = 805) and United States (n = 115) ( Supplementary Table 1 and Supplementary Methods). For controls, we used publicly available data on 2,912 individuals from the 1958 British Birth Cohort, genotyped on Illumina 1.2M Duo custom arrays. After applying prespecified quality control measures ( Supplementary Fig. 1 , Supplementary Table 2a,b and Supplementary Methods), we estimated ORs and 95% confidence intervals (CIs) for 447,760 autosomal SNPs with minor allele frequencies (MAFs) of ≥5% in 823 cases and 2,795 controls. Quantile-quantile plots of P values showed minimal inflation of test statistics, indicating that there was not substantial cryptic population substructure or differential genotyping between cases and controls (genomic control inflation factor λ = 1.05; Supplementary Fig. 2) .
A total of 17 SNPs, mapping to 6 independent genomic regions, showed evidence of association with male breast cancer at P ≤ 5.0 × 10 −7 (Supplementary Fig. 3 ). We attempted to validate the most significantly associated SNP mapping to each of the 6 regions in 438 cases and 474 controls recruited from 12 case-control series ( Supplementary Table 1 and Supplementary Methods). In a combined analysis, the associations of two SNPs, rs1314913 (P = 3.02 × 10 −13 ; OR = 1.57) and rs3803662 (P = 3.87 × 10 −15 ; OR = 1.50), attained genome-wide significance ( Table 1 Fig. 4 ). RAD51 family members function in both mitotic and meiotic homologous recombination and in DNA double-strand break repair. rs999737, located in intron 10 of RAD51B, has previously been shown to be associated with risk of female breast cancer 3 . This SNP maps approximately 335 kb telomeric to rs1314913 and is separated from it by strong recombination hotspots ( Fig. 1a and Supplementary Fig. 4 ). rs999737 and rs1314913 were only weakly correlated in the male breast cancer cases (r 2 = 0.02) and the HapMap Utah residents of Northern and Western European ancestry (CEU) population (r 2 = 0.006). To formally test for independence of the rs1314913 association signal from that of rs999737, we fitted a logistic regression model with data from the discovery phase samples adjusted for rs999737, obtaining an OR for rs1314913 of 1.54 (P = 1.04 × 10 −9 ). Conversely, the OR for rs999737 after adjustment for rs1314913 was 0.93 (P = 0.25).
To provide further insight into the association at 14q24.1, we imputed genotypes in cases and controls using data from the 1000 Genomes Project. Fifty-two imputed SNPs were more strongly associated with male breast cancer than rs1314913 and delineated an 85-kb cluster from 67.68 Mb to 67.77 Mb ( Fig. 1a and Supplementary  Table 5 ). To examine whether any directly genotyped or imputed SNPs annotated a putative transcription factor-binding site or enhancer element, we conducted a bioinformatic search of the region (Supplementary Methods). Seven associated SNPs, including rs1314913, were highly evolutionarily conserved (Supplementary Table 6 ). Analysis of Encyclopedia of DNA Elements (ENCODE) project data, including the Broad histone modification data sets for human mammary epithelial cells (HMECs), showed that two conserved SNPs, rs1314913 and an adjacent SNP, rs1316014, were located in a transcription factor-binding site, lying within a DNAse hypersensitive site flanked by regions of high histone H3 lysine 4 (H3K4) mono-or dimethylation and low trimethylation, features that are characteristic of enhancer elements (Supplementary Figs. 5 and 6) . In silico predictions are compatible with the minor alleles of both rs1314913 and rs1316014 abrogating the DNA binding sites of activator protein (AP)-1 and related transcription factors ( Supplementary  Fig. 7) . It is possible that the role of AP-1 in modulating estrogen signaling and transcription 4 might explain the association between rs1314913 and male breast cancer.
We have previously shown in a much smaller study that rs3803662, a synonymous SNP in LOC643714 mapping to chromosome 16q12.1 at 51,143,812 bp, was associated with male breast cancer risk, albeit not at genome-wide levels of significance 5 . Here, we provide robust confirmatory evidence of this association ( Table 1) . Examination of imputed data suggests that the association spans a 61-kb region from 51.09 Mb to 51.16 Mb that is proximal to LOC643174 (Fig. 1b) , with the associated region localizing to the TOX3 gene (encoding TOX high-mobility-group family member 3).
Rare variants in two breast cancer susceptibility genes, BRCA2 and CHEK2, have larger ORs in males compared with females 2,6 , and we show here that this is also true for two common susceptibility alleles. Both rs1314913 and rs3803662 are notable because of the magnitude of their effects. Comparing the breast cancer OR for rs3803662 in our data with the published estimate for females (OR = 1.20 (1.16-1.24)) 7 , we found that the effect was significantly greater in males (P = 7.76 × 10 −5 ). Because rs1314913 represents a new breast cancer susceptibility locus, there are no equivalent estimates in females for comparison.
Variants at 24 loci have so far been shown to influence female breast cancer risk 3, [7] [8] [9] [10] [11] [12] [13] [14] . The associations of these variants with male breast cancer are shown in Supplementary Table 7 . In addition to rs3803662, SNPs at 2q35, 6q25.1, 10q21.2, 11q13.3 and 12p11.22 were significantly associated at P < 0.05. Loci at 3p24.1, 9p21.3 and 14q24.1 showed borderline associations at P ≤ 0.1. There was no significant association, however, between variants at the FGFR2 locus on chromosome 10q26.13 and male breast cancer risk (rs2981582; OR = 1.07 (0.96-1.20); P = 0.21). This observation is unexpected because male breast cancer is almost entirely estrogen receptor positive. rs2981582 is the SNP with the strongest known association with estrogen receptor-positive breast cancer in females 15 , and the power of our study to detect an allele npg with the same effect size as in female breast cancer at P ≤ 0.05 was close to 100%. rs3803662, however, is strongly associated with both estrogen receptor-negative and estrogen receptor-positive breast cancer in females 15 . Therefore, the estrogen receptor status of male breast cancers does not provide an obvious explanation for the observed SNP associations. These data provide evidence for low-penetrance susceptibility to male breast cancer. Given the modest size of our study, it is likely that additional risk variants can be identified by future GWAS. Note: Supplementary information is available in the online version of the paper.
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